RxDoctor Payments Data

Renny Abraham, MD

Internal Medicine · Oxford, MINPI 1811995673

Payments from drug & device makers

$5,417in general payments, 2019–2025

Across 347 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$777
  • Lilly USA, LLC$670
  • Pfizer$524
  • GSK$292
  • Supernus Pharmaceuticals, Inc.$209
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$5,38599%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,417 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$458,531
Medicare patients
949
Services billed
6,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban192$175,817
OzempicSemaglutide93$120,542
MounjaroTirzepatide91$107,674
JardianceEmpagliflozin58$84,441
TrulicityDulaglutide25$52,706
EntrestoSacubitril/Valsartan53$41,640
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$40,021
XareltoRivaroxaban33$33,616
FarxigaDapagliflozin Propanediol33$28,027
JanuviaSitagliptin Phosphate16$21,050
PaxlovidNirmatrelvir/Ritonavir29$12,462
Fosfomycin Tromethamine35$11,102
ShingrixVaricella-Zoster Ge/As01b/Pf44$9,787
LinzessLinaclotide18$8,537
Atorvastatin Calcium540$8,054

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid, Abrysvo$524$191,767232 claims
Lilly USA, LLCMounjaro, Trulicity$670$160,380116 claims
Novo NordiskOzempic$777$120,54293 claims
Boehringer IngelheimJardiance$54$84,44158 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$292$55,486105 claims
NovartisEntresto$57$41,64053 claims
AstraZenecaFarxiga, Brilinta$12$32,32751 claims
MerckJanuvia$192$21,05016 claims
AbbVieLinzess$1,000$8,53718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Oxford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →